ArticleClinical rheumatology2026
Prognostic value of cardiopulmonary exercise testing in connective tissue disease-associated pulmonary arterial hypertension at low and intermediate-low risk.
Article in Clinical rheumatology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
backgroundPulmonary arterial hypertension (PAH) is a severe complication of connective tissue disease (CTD) and a leading cause of mortality in affected patients. Although the COMPERA 2.0 model is widely used for risk stratification in PAH, its ability to discriminate prognosis among low-risk patients remains limited. This study aimed to explore the prognostic predictive role of cardiopulmonary exercise testing (CPET) in CTD-PAH patients classified as low or intermediate-low risk by COMPERA 2.0.
methodsThis ambispective cohort included 33 CTD-PAH patients confirmed by right heart catheterization (RHC) and classified as low or intermediate-low risk via COMPERA 2.0 after standardized therapy. All patients underwent CPET. According to the 2022 ESC/ERS criteria, participants were stratified by peak oxygen uptake (PeakVO
resultsThe non-attainment group presented with significantly worse baseline and follow-up characteristics, including reduced exercise tolerance, higher N-terminal pro-brain natriuretic peptide (NT-proBNP) levels, and more impaired echocardiographic and hemodynamic parameters compared to the attainment group. Over a mean follow-up of 23.7 ± 12.3 months, the non-attainment group had significantly poorer event-free survival (p = 0.031).
conclusionsCPET provides additional prognostic information beyond COMPERA 2.0, identifying CTD-PAH patients with greater disease severity and a higher risk of adverse outcomes, even within the low and intermediate-low risk strata. Failure to achieve CPET thresholds was independently associated with increased disease burden and reduced event-free survival. Key Points • This study demonstrates that cardiopulmonary exercise testing (CPET) offers significant prognostic value beyond the COMPERA 2.0 risk stratification model in patients with connective tissue disease-associated pulmonary arterial hypertension (CTD-PAH) classified as low or intermediate-low risk. • Patients failing to meet CPET criteria (PeakVO₂ > 15 mL/min/kg and VE/VCO₂ slope < 36) exhibited more severe disease, including worse hemodynamics, right ventricular dysfunction, and higher NT-proBNP levels, despite similar COMPERA 2.0 risk categories. • The CPET non-attainment group had significantly lower event-free survival, underscoring the utility of CPET in identifying high-risk patients who might otherwise be underestimated by conventional risk assessment tools. • Inadequate use of immunosuppressive therapy in the non-attainment group suggests that optimizing management of the underlying connective tissue disease may be critical for improving cardiopulmonary outcomes in CTD-PAH.
Indexed as
Identifiers
41917538What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.